JNK3 as a therapeutic target for neurodegenerative diseases.

Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.
Journal of Alzheimer's disease: JAD (Impact Factor: 4.17). 02/2011; 24(4):633-42. DOI: 10.3233/JAD-2011-091567
Source: PubMed

ABSTRACT c-Jun N-terminal kinases (JNKs) and in particular JNK3 the neuronal specific isoform, have been recognized as important enzymes in the pathology of diverse neurological disorders. Indeed, several efforts have been made to design drugs that inhibit JNK signaling. The success that characterized the new generation of cell permeable peptides raise the hope in the field of neurodegeneration for new therapeutic routes. However, in order to design new and more efficient therapeutical approaches careful re-examination of current knowledge is required. Scaffold proteins are key endogenous regulators of JNK signaling: they can modulate spatial and temporal activation of the JNK signaling and can thus provide the basis for the design of more specific inhibitors. This review focuses on delineating the role of scaffold proteins on the regulation of JNK signaling in neurons. Furthermore the possibility to design a new JNK3 cell permeable peptide inhibitor by targeting the β-arrestin-JNK3 interaction is discussed.

1 Bookmark
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Introduction: Diabetic neuropathy leads to sensory neurons abnormality. But, injury signaling mechanisms are not well documented. So, the aim of present study was to investigate SYD gene expression in spinal nerve of wistar male rats with diabetic neuropathy. Methods: 12 wistar male rats randomly assigned in 3 groups: diabetic trained, diabetic untrained and healthy control. For inducing diabetes, intraperitoneal injection of STZ solution (45 mg/Kg) method was used. Two weeks after STZ injection, diabetic neuropathy was demonstrated with mechanical allodynia and thermal hyperalgesia tests, after which moderate endurance training protocol was performed for 6 weeks. 24 hours after final training session, the rats were dissected and L4-L6 sensory neurons of spinal cord tissue were removed. Also SYD gene expression was performed with Real time- PCR methods. Findings: SYD gene expression in diabetic untrained group was higher than healthy control group (p=0/001). Also, compared with diabetic untrained group, training significantly decreased SYD gene expression and blood glucose levels in diabetic trained group. (P=0/001 and P=0/0001, respectively). Conclusion: In sensory neurons of diabetic rats mRNA SYD up-regulation, is involved in neuronal injury signaling and training as a non-pharmacotherapy strategy can modulate and get it close to normal levels. So, it is suggested that SYD should be noted as a novel treatment in diabetes disease, however there are other related points which should be explained by future studies. Key words: Diabetic neuropathy, Endurance training, Gene expression, SYD
    Iranian Journal of Diabetes and Lipid Disorders 01/2013; 12(4):292-301.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although arrestins bind dozens of non-receptor partners, the interaction sites for most signaling proteins remain unknown. Here we report the identification of arrestin-3 elements involved in binding MAP kinase JNK3α2. Using purified JNK3α2 and MBP fusions containing separated arrestin-3 domains and peptides exposed on the non-receptor-binding surface of arrestin-3 we showed that both domains bind JNK3α2 and identified one element on the N-domain and two on the C-domain that directly interact with JNK3α2. Using in vitro competition we confirmed that JNK3α2 engages identified N-domain element and one of the C-domain peptides in the full-length arrestin-3. The 25-amino acid N-domain element has the highest affinity for JNK3α2, suggesting that it is the key site for JNK3α2 docking. The identification of elements involved in protein-protein interactions paves the way to targeted redesign of signaling proteins to modulate cell signaling in desired ways. The tools and methods developed here to elucidate the molecular mechanism of arrestin-3 interactions with JNK3α2 are suitable for mapping of arrestin-3 sites involved in interactions with other partners.
    Cellular signalling 01/2014; · 4.09 Impact Factor

Full-text (2 Sources)

Available from
Jun 4, 2014

Similar Publications